TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Problems
A focus on progestogens in hormone replacement therapy
Key Statistics
- 12–14 days — Minimum sequential progestogen/month
- 100 mg — Micronised progesterone, daily continuous
- +8–10/1000 — Excess breast cancers, 5y combined HRT
Don't-miss facts
-
Uterus present + estrogen = progestogen required. Sequential 12–14 days/month; continuous only if >1 year post- menopause
-
Micronised progesterone: 200 mg ×12–14 days/month sequential; 100 mg daily continuous. Vaginal dose = oral dose (off- licence)
-
Only Mirena® 52 mg licensed for endometrial protection (4 years). Jaydess®/Kyleena® need additional progestogen
-
Persistent unscheduled bleeding >4 months → alter dose/route → USS: biopsy/hysteroscopy if ET ≥4 mm continuous or ≥7 mm sequential
-
VTE risk factors → transdermal estrogen + oral micronised progesterone or combined patch. Oral HRT ↑VTE 2–4×, worst in year 1
-
Breast cancer: combined HRT +8 to +10 extra cases/1000 over 5 years (age 50–59) – comparable to obesity (+10) and alcohol (+8 to +11)
-
Remove the LNG-IUS on diagnosis of breast cancer; personal history of breast cancer usually contraindicates systemic HRT
-
Debilitating progestogenic mood effects → halve dose or 7–10 days/month (warn ↑hyperplasia risk), or switch to LNG-IUS / patch / vaginal route
Progestogen risk profile at a glance
Lowest VTE/breast risk: micronised progesterone, dydrogesterone Fewest systemic side effects: LNG-IUS, vaginal progesterone
Highest VTE: oral estrogen + MPA (OR 2.10) Not for HRT in UK: norpregnanes, progestogen cream
Abbreviation Key
- HRT — hormone replacement therapy
- WHIMS — WHI Memory Study
- PR — progesterone receptor
- PEPI — Postmenopausal Estrogen/Progestin Interventions trial
- MPA — medroxyprogesterone acetate
- CGHFBC — Collaborative Group on Hormonal Factors in Breast Cancer
- NET — norethisterone
- VTE — venous thromboembolism
- LNG-IUS — levonorgestrel intrauterine system
- BMS — British Menopause Society
- CEE — conjugated equine estrogen
- HR / RR / OR — hazard ratio / relative risk / odds ratio
- WHI — Women’s Health Initiative
Source: Ghosh S, Imrie R, Goadsby J, Savvas M. A focus on progestogens in hormone replacement therapy. The Obstetrician & Gynaecologist 2023;25:263–271. doi:10.1111/tog.12898
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).